CERS - Cerus Corporation
| Previous Close | 4.8200 |
| Open | 4.8300 |
| Bid | 4.7000 x 2200 |
| Ask | 4.9200 x 4000 |
| Day's Range | 4.7400 - 4.9851 |
| 52 Week Range | 3.7000 - 6.8800 |
| Volume | 1,562,688 |
| Avg. Volume | 1,329,819 |
| Market Cap | 778.884M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5130 |
| Earnings Date | Feb 19, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 |
- Business Wire
Cerus Corporation to Release Fourth Quarter and Full Year 2019 Financial Results on February 20, 2020
Cerus Corporation (Nasdaq:CERS) announced today that its fourth quarter and full year 2019 financial results will be released on Thursday, February 20, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
- Simply Wall St.
Trade Alert: The Independent Director Of Cerus Corporation (NASDAQ:CERS), Franklin Witney, Has Just Spent US$100k Buying Shares
Whilst it may not be a huge deal, we thought it was good to see that the Cerus Corporation (NASDAQ:CERS) Independent...
- Business Wire
Cerus Corporation Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Cerus Corporation (Nasdaq: CERS) announced today the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Total proceeds for the offering were $63.3 million, before deducting estimated offering expenses payable by Cerus.
- Business Wire
Cerus Corporation Announces Pricing of Upsized Public Offering of Common Stock
Cerus Corporation (Nasdaq: CERS) announced today the pricing of a registered underwritten public offering of its common stock for proceeds of approximately $55.0 million, before deducting estimated offering expenses payable by Cerus. The offering is expected to close January 31, 2020, subject to customary closing conditions. All of the shares sold in the offering were sold by Cerus. In addition, Cerus has granted the underwriter a 30-day option to purchase up to an additional $8.25 million of shares of its common stock. On January 28, 2020, the last sale price of the shares as reported on The Nasdaq Global Market was $4.15 per share.
- Business Wire
Cerus Corporation Announces Public Offering of Common Stock
Cerus Corporation (Nasdaq: CERS) announced today that it has commenced a registered underwritten public offering of $50.0 million of its common stock. In addition, Cerus expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of the shares to be sold in the offering are to be sold by Cerus.
- Benzinga
13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
- Business Wire
Coronavirus Inactivation Reported in Recent INTERCEPT Blood System Publication in Transfusion Medicine
Cerus Corporation (Nasdaq:CERS) today announced the publication of a study in Transfusion Medicine1 on the inactivation of the MERS (Middle Eastern Respiratory Syndrome) coronavirus in human platelet concentrates using the INTERCEPT Blood System for platelets. This study follows prior publications on the inactivation of the MERS coronavirus in human plasma2 and the inactivation of the SARS (Severe Acute Respiratory Syndrome) coronavirus in human platelets3. A new coronavirus outbreak is currently ongoing in China, with the first imported U.S. case confirmed on Tuesday. The genetic sequence of the new coronavirus, 2019-nCoV, is at least 70% similar to SARS-CoV4.
- Business Wire
French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use
Cerus Corporation (Nasdaq:CERS) is pleased to announce the recent publication of the 16th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of medicine and other health products. The report highlights the safety and effectiveness of INTERCEPT platelets during the first full year of routine use.
- Business Wire
Cerus Corporation Announces Preliminary Fourth Quarter and Full Year 2019 Product Revenue
Cerus Corporation (Nasdaq:CERS) announced today preliminary product revenue for the fourth quarter and full year 2019 and provided 2020 product revenue guidance.
- Simply Wall St.
Is Cerus (NASDAQ:CERS) Using Debt Sensibly?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- Insider Monkey
Cerus Corporation (CERS): Are Hedge Funds Right About This Stock?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Thomson Reuters StreetEvents
Edited Transcript of CERS earnings conference call or presentation 30-Oct-19 8:30pm GMT
Q3 2019 Cerus Corp Earnings Call
- Simply Wall St.
How Should Investors React To Cerus Corporation's (NASDAQ:CERS) CEO Pay?
Obi Greenman has been the CEO of Cerus Corporation (NASDAQ:CERS) since 2011. First, this article will compare CEO...
- Insider Monkey
Were Hedge Funds Right About Cashing Out Of Cerus Corporation (CERS)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
- Benzinga
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
- Zacks
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of -18.18% and 2.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Will Cerus (CERS) Report Negative Earnings Next Week? What You Should Know
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
How Much Are Cerus Corporation (NASDAQ:CERS) Insiders Taking Off The Table?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
